Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening

Study Overview
=================
Brief Summary
-----------------
This study examines prevention and early detection of cervical cancer through self-administration screening of patients in Western Uganda. The cervix is the opening of the uterus or womb, which is the organ that supports babies before they are born. There are simple tests that let doctors know whether or not patients have cells that may become cancer. Some of the tests determine whether patients have an increased risk for cervical disease, but they do not actually confirm that they have it: these are called screening tests. This study may help researchers determine how to best deliver cervical cancer prevention services using the HPV test.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To establish the acceptance and correlates of self-collected human papillomavirus (HPV)-ribonucleic acid (RNA) testing among women in the rural Ugandan community as well as the incidence and determinants of successful completion of the cervical cancer screening cascade from self-collected HPV testing to receipt of results. II. To ascertain the frequency and determinants of successful acquisition of treatment among women who have HPV detected on self-collected swabs in rural Uganda. III. To derive population-based estimates of the prevalence of high-risk HPV and cervical intraepithelial neoplasia (CIN) detected through community-based screening employing self-collected HPV RNA testing in rural Uganda. OUTLINE: Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.

Official Title
-----------------
Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening in the Community

Conditions
-----------------
Cervical Carcinoma, Human Papillomavirus-Related Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: HPV testing
* Other: Questionnaire Administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women in the three Ugandan districts (Kiboga, Kyankwanzi and Hoima) who access screening during the community health campaigns Age 25-49 years Resident in the study district Provision of informed consent Exclusion Criteria: Clinical signs and symptoms of cancer of the cervix

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Screening<br>Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer. | Diagnostic Test: HPV testing<br>* Undergo collection of cervical samples for HPV testing<br>Other: Questionnaire Administration<br>* Complete questionnaires<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who complete screening | The absolute number of participants successfully completing screening. | 1 day | 
| Proportion of women 25-49 years of age who complete screening | Overall proportions of women 25-49 years old successfully completing cervical cancer screening. | 1 day | 
| Proportion of participants who receive treatment after a positive screening result | Proportion of participants who receive treatment after screening positive for high-risk human papillomavirus (HPV) will be calculated with a 95% confidence interval. | 6 months | 
| Proportion of participants with positive, high-risk human papillomavirus (HPV) | Prevalence of participants with positive high-risk human papillomavirus (HPV) | 1 day | 
| Proportion of participants with cervical intraepithelial neoplasia (CIN2)+ | Proportion of participants with cervical intraepithelial neoplasia (CIN2)+ | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical Cancer Screening, Human Papillomavirus, HPV